Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Oncolytics Biotech Inc. - Common Stock
(NQ:
ONCY
)
0.8094
+0.0194 (+2.46%)
Streaming Delayed Price
Updated: 10:37 AM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
176,300
Open
0.8052
Bid (Size)
0.8080 (1,000)
Ask (Size)
0.8094 (200)
Prev. Close
0.7900
Today's Range
0.7929 - 0.8189
52wk Range
0.3258 - 1.510
Shares Outstanding
46,166,980
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
May 14, 2026
From
World Street Intelligence
Via
GlobeNewswire
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
March 19, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Performance
YTD
-17.7%
-17.7%
1 Month
-27.7%
-27.7%
3 Month
-19.1%
-19.1%
6 Month
-18.4%
-18.4%
1 Year
+92.3%
+92.3%
More News
Read More
Registration Momentum Builds Across the Oncology Pipeline
February 17, 2026
From
USA News Group
Via
GlobeNewswire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
From
Equity Insider
Via
GlobeNewswire
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug
↗
February 04, 2026
Via
Stocktwits
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
January 26, 2026
From
Equity Insider
Via
GlobeNewswire
Top movers in Tuesday's after hours session
↗
January 20, 2026
Via
Chartmill
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
January 14, 2026
From
USA News Group
Via
GlobeNewswire
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
January 14, 2026
From
USA News Group
Via
GlobeNewswire
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
January 12, 2026
From
Equity Insider
Via
GlobeNewswire
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
January 08, 2026
From
Equity Insider
Via
GlobeNewswire
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
January 08, 2026
From
Oncolytics Biotech Inc.
Via
Business Wire
THE CHOKE POINT: 5 Assets That Control the Bottleneck
January 07, 2026
From
Equity Insider
Via
GlobeNewswire
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
January 07, 2026
From
Oncolytics Biotech Inc.
Via
Business Wire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
From
Equity Insider
Via
GlobeNewswire
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
December 16, 2025
From
Oncolytics Biotech Inc.
Via
Business Wire
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
December 15, 2025
From
USA News Group
Via
GlobeNewswire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
December 12, 2025
From
Equity Insider
Via
GlobeNewswire
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
December 09, 2025
From
Oncolytics Biotech Inc.
Via
Business Wire
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
December 06, 2025
From
USA News Group
Via
GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Thursday?
↗
December 04, 2025
Via
Chartmill
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
December 03, 2025
From
USA News Group
Via
GlobeNewswire
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
December 03, 2025
From
USA News Group
Via
GlobeNewswire
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
November 20, 2025
From
Oncolytics Biotech Inc.
Via
Business Wire
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
Via
FinancialNewsMedia
Frequently Asked Questions
Is Oncolytics Biotech Inc. - Common Stock publicly traded?
Yes, Oncolytics Biotech Inc. - Common Stock is publicly traded.
What exchange does Oncolytics Biotech Inc. - Common Stock trade on?
Oncolytics Biotech Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oncolytics Biotech Inc. - Common Stock?
The ticker symbol for Oncolytics Biotech Inc. - Common Stock is ONCY on the Nasdaq Stock Market
What is the current price of Oncolytics Biotech Inc. - Common Stock?
The current price of Oncolytics Biotech Inc. - Common Stock is 0.8094
When was Oncolytics Biotech Inc. - Common Stock last traded?
The last trade of Oncolytics Biotech Inc. - Common Stock was at 05/22/26 10:37 AM ET
What is the market capitalization of Oncolytics Biotech Inc. - Common Stock?
The market capitalization of Oncolytics Biotech Inc. - Common Stock is 37.37M
How many shares of Oncolytics Biotech Inc. - Common Stock are outstanding?
Oncolytics Biotech Inc. - Common Stock has 37M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
